Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPIRE 1 bococizumab cardiovascular outcomes trial
NL-OMON44718Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cardiac morbidity, dyslipidemia and hypercholesterolemia comparing Bococizumab plus background lipid-lowering therapy with Placebo plus background lipid-lowering therapy (2 arms). Primary endpoint: Primary composite major cardiovascular event endpoint. Started Mar 2014; status: active, not recruiting.
02
Drugs
bococizumab
03
Conditions
cardiac morbiditydyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on NL-OMON44718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44718.